Tags

Type your tag names separated by a space and hit enter

An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women.
Contraception 2004; 69(1):23-6C

Abstract

This study was conducted to compare the cycle control, efficacy and adverse events of a new low-dose oral contraceptive pill regimen containing 3 mg drospirenone (DRSP)/30 microg ethinylestradiol (EE), with a widely prescribed 150 microg levonogestrel (LNG)/30 microg EE. The results of this comparative trial demonstrated that the two preparations had no statistically significant difference in terms of cycle control, efficacy and adverse events. The occurrence of spotting and breakthrough bleeding was low and was not different between the two regimens. There was neither amenorrhea nor pregnancies reported in either group. The most common adverse events in both groups were nausea, headache and breast tenderness. Also statistically significant changes were found in body weight and blood pressure in both groups at the end of the study. In conclusion, the 3 mg DRSP/30 microg EE regimen provides good cycle control with reliable contraceptive efficacy and a low incidence of adverse events equal to the 150 microg LNG/30 microg EE preparation. Compared with the 150 microg LNG/30 microg EE preparation, the 3 mg DRSP/30 microg EE preparation demonstrated a more favorable effect on body weight and blood pressure, with the mean body weight and mean blood pressure remaining lower than baseline mean. The new formulation may be especially beneficial for women susceptible to body weight gain and rise in blood pressure.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Rama IV Road, Bangkok 10330, Thailand.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

14720615

Citation

Suthipongse, Wichit, and Surasak Taneepanichskul. "An Open-label Randomized Comparative Study of Oral Contraceptives Between Medications Containing 3 Mg Drospirenone/30 Microg Ethinylestradiol and 150 Microg Levonogestrel/30 Microg Ethinylestradiol in Thai Women." Contraception, vol. 69, no. 1, 2004, pp. 23-6.
Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. Contraception. 2004;69(1):23-6.
Suthipongse, W., & Taneepanichskul, S. (2004). An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. Contraception, 69(1), pp. 23-6.
Suthipongse W, Taneepanichskul S. An Open-label Randomized Comparative Study of Oral Contraceptives Between Medications Containing 3 Mg Drospirenone/30 Microg Ethinylestradiol and 150 Microg Levonogestrel/30 Microg Ethinylestradiol in Thai Women. Contraception. 2004;69(1):23-6. PubMed PMID: 14720615.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. AU - Suthipongse,Wichit, AU - Taneepanichskul,Surasak, PY - 2004/1/15/pubmed PY - 2004/5/11/medline PY - 2004/1/15/entrez SP - 23 EP - 6 JF - Contraception JO - Contraception VL - 69 IS - 1 N2 - This study was conducted to compare the cycle control, efficacy and adverse events of a new low-dose oral contraceptive pill regimen containing 3 mg drospirenone (DRSP)/30 microg ethinylestradiol (EE), with a widely prescribed 150 microg levonogestrel (LNG)/30 microg EE. The results of this comparative trial demonstrated that the two preparations had no statistically significant difference in terms of cycle control, efficacy and adverse events. The occurrence of spotting and breakthrough bleeding was low and was not different between the two regimens. There was neither amenorrhea nor pregnancies reported in either group. The most common adverse events in both groups were nausea, headache and breast tenderness. Also statistically significant changes were found in body weight and blood pressure in both groups at the end of the study. In conclusion, the 3 mg DRSP/30 microg EE regimen provides good cycle control with reliable contraceptive efficacy and a low incidence of adverse events equal to the 150 microg LNG/30 microg EE preparation. Compared with the 150 microg LNG/30 microg EE preparation, the 3 mg DRSP/30 microg EE preparation demonstrated a more favorable effect on body weight and blood pressure, with the mean body weight and mean blood pressure remaining lower than baseline mean. The new formulation may be especially beneficial for women susceptible to body weight gain and rise in blood pressure. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/14720615/An_open_label_randomized_comparative_study_of_oral_contraceptives_between_medications_containing_3_mg_drospirenone/30_microg_ethinylestradiol_and_150_microg_levonogestrel/30_microg_ethinylestradiol_in_Thai_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010782403002300 DB - PRIME DP - Unbound Medicine ER -